|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
de Vos II, Remmers S, Hogenhout R and
Roobol MJ; ERSPC Rotterdam Study Group, : Prostate cancer mortality
among elderly men after discontinuing organised screening:
Long-term results from the European randomized study of screening
for prostate cancer Rotterdam. Eur Urol. 85:74–81. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hogenhout R, Remmers S, van
Slooten-Midderigh ME, de Vos II and Roobol MJ; ERSPC Rotterdam
Study Group, : From screening to mortality reduction: An overview
of empirical data on the patient journey in European randomized
study of screening for prostate cancer Rotterdam after 21 years of
follow-up and a reflection on quality of life. Eur Urol Oncol.
7:713–720. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roobol MJ, de Vos II, Månsson M, Godtman
RA, Talala KM, den Hond E, Nelen V, Villers A, Poinas G,
Kwiatkowski M, et al: European study of prostate cancer
screening-23-year Follow-up. N Engl J Med. 393:1669–1680. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Caruana M, Gulati R, Etzioni R, Barratt A,
Armstrong BK, Chiam K, Nair-Shalliker V, Luo Q, Bang A, Grogan P,
et al: Benefits and harms of prostate specific antigen testing
according to Australian guidelines. Int J Cancer. 154:648–658.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stroomberg HV, Larsen SB, Kjær Nielsen T,
Helgstrand JT, Brasso K and Røder A: Outcomes of biopsy grade group
1 prostate cancer diagnosis in the Danish population. Eur Urol
Oncol. 7:770–777. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waeckel T, Ait Said K, Altieri M, Belin A,
Doerfler A and Tillou X: Over-diagnosed prostate cancer in solid
organ recipients: Lessons from the last 3 decades. Int Urol
Nephrol. 53:241–248. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Vos II, Rosenstand C, Hogenhout R, van
den Bergh RCN, Remmers S and Roobol MJ; ERSPC Rotterdam Study
Group, : Reducing overtreatment of prostate cancer patients:
Revisiting the European association of urology pretreatment risk
group classification using Long-term Follow-up data from the
European randomized study of screening for prostate cancer
Rotterdam. Eur Urol Oncol. 8:747–754. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ficarra V, Bartoletti R, Borghesi M, DE
Nunzio C, Falagario UG, Gandaglia G, Giannarini G, Minervini A,
Mirone V, Porpiglia F, et al: Prostate cancer diagnostic pathway in
men with lower urinary tract symptoms or performing opportunistic
screening: The Italian Society of Urology (SIU) position paper.
Minerva Urol Nephrol. 76:530–535. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beatrici E, De Carne F, Frego N, Moretto
S, Paciotti M, Fasulo V, Uleri A, Garofano G, Avolio PP, Chiarelli
G, et al: Optimizing prostate cancer diagnostic Work-up through
Micro-ultrasound: Minimizing unnecessary procedures and reducing
overdiagnoses. Prostate. 85:603–611. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Basin MF, Crane K, Basnet A, Chandrasekar
T, Shapiro O, Jacob JM, Bratslavsky G and Goldberg H: Disparities
associated with shared Decision-making in prostate cancer
screening. Eur Urol Focus. 9:1008–1015. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanchis MJ, Guilabert M, Parker LA,
Caballero-Romeu JP, Chilet-Rosell E, Gómez-Pérez L, Alonso-Coello
P, Cebrián A, López-Garrigós M, Moral I, et al: Perspectives of
clinicians and screening candidates on shared decision-making in
prostate cancer screening with the prostate-specific antigen (PSA)
test: A qualitative study (PROSHADE study). BMJ Evid Based Med.
30:163–172. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carlsson SV, Arnsrud Godtman R, Pihl CG,
Vickers A, Lilja H, Hugosson J and Månsson M: Young age on starting
Prostate-specific antigen testing is associated with a greater
reduction in prostate cancer mortality: 24-year Follow-up of the
Göteborg randomized Population-based prostate cancer screening
trial. Eur Urol. 83:103–109. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammadi T, Guh DP, Tam ACT, Pataky RE,
Black PC, So A, Lynd LD, Zhang W and Conklin AI: Economic
evaluation of prostate cancer risk assessment methods: A
cost-effectiveness analysis using population data. Cancer Med.
12:20106–20118. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Basourakos SP, Gulati R, Vince RA Jr,
Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC,
Barbieri CE, et al: Harm-to-Benefit of three decades of prostate
cancer screening in black men. NEJM Evid. 1:102022. View Article : Google Scholar
|
|
16
|
Sweis J, Ofori B and Murphy AB: Concerns
regarding prostate cancer screening guidelines in minority
populations. Prostate Cancer Prostatic Dis. 27:591–593. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vettenranta A, Murtola TJ, Talala K, Taari
K, Stenman UH, Tammela TLJ and Auvinen A: Outcomes of prostate
cancer screening among men using antidiabetic medication. Sci Rep.
11:73632021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vettenranta A, Murtola TJ, Raitanen J,
Raittinen P, Talala K, Taari K, Stenman UH and Tammela TLJ:
Outcomes of screening for prostate cancer among men who use
statins. JAMA Oncol. 8:61–68. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wallström J, Geterud K, Kohestani K, Maier
SE, Pihl CG, Socratous A, Stranne J, Arnsrud-Godtman R, Månsson M,
Hellström M and Hugosson J: Prostate cancer screening with magnetic
resonance imaging: Results from the second round of the Göteborg
prostate cancer screening 2 trial. Eur Urol Oncol. 5:54–60. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Padhani AR and Schoots IG: Prostate cancer
screening-stepping forward with MRI. Eur Radiol. 33:6670–6676.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nordström T, Annerstedt M, Glaessgen A,
Carlsson S, Clements M, Abbadi A, Grönberg H, Jäderling F, Eklund M
and Discacciati A: Repeated prostate cancer screening using
Prostate-specific antigen testing and magnetic resonance imaging: A
secondary analysis of the STHLM3-MRI randomized clinical trial.
JAMA Netw Open. 7:e23545772024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Callender T, Emberton M, Morris S, Pharoah
PDP and Pashayan N: Benefit, harm, and cost-effectiveness
associated with magnetic resonance imaging before biopsy in
Age-based and Risk-stratified screening for prostate cancer. JAMA
Netw Open. 4:e20376572021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hao S, Heintz E, Östensson E, Discacciati
A, Jäderling F, Grönberg H, Eklund M, Nordström T and Clements MS:
Cost-Effectiveness of the Stockholm3 test and magnetic resonance
imaging in prostate cancer screening: A microsimulation study. Eur
Urol. 82:12–19. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Josefsson A, Månsson M, Kohestani K,
Spyratou V, Wallström J, Hellström M, Lilja H, Vickers A, Carlsson
SV, Godtman R and Hugosson J: Performance of 4 Kscore as a reflex
test to Prostate-specific antigen in the GÖTEBORG-2 prostate cancer
screening trial. Eur Urol. 86:223–229. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferro M, De Cobelli O, Crocetto F, Carbone
G, Mirto BF, Fiorenza M, Falcone A, La Civita E, Fallara G, Musi G,
et al: Lower PHI, [-2]proPSA/fPSA and testosterone/estradiol ratios
in healthy black men: Preliminary results and potential
implications in prostate cancer clinical management. Minerva Urol
Nephrol. 77:52–56. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim J, Shim JS, Han BH, Kim HJ, Park J,
Cho IJ, Kang SG, Kang JY, Bong KW and Choi N: Hydrogel-based
hybridization chain reaction (HCR) for detection of urinary
exosomal miRNAs as a diagnostic tool of prostate cancer. Biosens
Bioelectron. 192:1135042021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tosoian JJ, Dunn RL, Niknafs YS, Saha A,
Vince RA Jr, St Sauver JL, Jacobson DJ, McGree ME, Siddiqui J,
Groskopf J, et al: Association of urinary MyProstateScore, Age, and
prostate volume in a longitudinal cohort of healthy men: Long-term
findings from the olmsted county study. Eur Urol Open Sci.
29:30–35. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kemesiene J, Nicolau C, Cholstauskas G,
Zviniene K, Lopeta M, Veneviciute S, Asmenaviciute I, Tamosauskaite
K, Pikuniene I and Jievaltas M: Performance of PCA3 and TMPRSS2:
ERG within the prostate cancer prevention trial risk calculator
version 2 in a lithuanian cohort. Res Rep Urol. 17:95–103.
2025.PubMed/NCBI
|
|
29
|
Amini AE, Hunter AE, Almashad A, Feng AJ,
Patel ND, O'Dea MR, McCormick SR, Rodgers LH and Salari K: Magnetic
resonance Imaging-based prostate cancer screening in carriers of
pathogenic germline mutations: Interim results from the initial
screening round of the prostate cancer genetic risk evaluation and
screening study. Eur Urol Oncol. 7:1358–1366. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McHugh JK, Bancroft EK, Saunders E, Brook
MN, McGrowder E, Wakerell S, James D, Rageevakumar R, Benton B,
Taylor N, et al: Assessment of a polygenic risk score in screening
for prostate cancer. N Engl J Med. 392:1406–1417. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang CM, Yuan L, Liu XH, Chen SQ, Wang HF,
Dong QF, Zhang B, Huang MS, Zhang ZY, Xiao J and Tao T: Developing
a diagnostic model for predicting prostate cancer: A retrospective
study based on Chinese multicenter clinical data. Asian J Androl.
26:34–40. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Björnebo L, Discacciati A, Falagario U,
Vigneswaran HT, Jäderling F, Grönberg H, Eklund M, Nordström T and
Lantz A: Biomarker vs MRI-Enhanced strategies for prostate cancer
screening: The STHLM3-MRI randomized clinical trial. JAMA Netw
Open. 7:e2471312024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Discacciati A, Abbadi A, Clements MS,
Annerstedt M, Carlsson S, Grönberg H, Jäderling F, Eklund M and
Nordström T: Repeat prostate cancer screening using Blood-based
risk prediction or Prostate-specific antigen in the era of magnetic
resonance Imaging-guided Biopsies: A secondary analysis of the
STHLM3-MRI randomized clinical trial. Eur Urol Oncol. 8:1466–1473.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muchadeyi MT, Hao S, Hernandez-Villafuerte
K, Khan SA, Becker N, Krilaviciute A, Seibold P, Gulati R, Albers
P, Schlander M and Clements M: Cost effectiveness analysis of
prostate cancer screening strategies in Germany: A microsimulation
study. Int J Cancer. 157:1662–1679. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nevalainen J, Raitanen J, Natunen K,
Kilpeläinen T, Rannikko A, Tammela T and Auvinen A: Early detection
of clinically significant prostate cancer: Protocol summary and
statistical analysis plan for the ProScreen randomised trial. BMJ
Open. 14:e0755952024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lawisch GKDS, Dexheimer GM, Biolchi V,
Seewald RA and Chies JAB: Prostate tumor markers: Diagnosis,
prognosis and management. Genet Mol Biol. 46 (3 Suppl
1):e202301362024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng YT, Chiang CH, Pu YS, Liu SP, Lu YC,
Chang YK, Chang HC, Huang KH, Lee YJ, Chow PM, et al: The
application of p2PSA% and prostate health index in prostate cancer
detection: A prospective cohort in a tertiary medical center. J
Formos Med Assoc. 118:260–267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Othman H, Abu Yamin AH, Md Isa N, Bahadzor
B and Syed Zakaria SZ: Diagnostic performance of prostate health
index (PHI) in predicting prostate cancer on prostate biopsy.
Malays J Pathol. 42:209–214. 2020.PubMed/NCBI
|
|
39
|
Nagata M: Editorial Comment from Dr Nagata
to Diagnostic performance of prostate cancer antigen 3 and the
Prostate Health Index in detecting overall and clinically
significant prostate cancer in men at first biopsy: A
meta-analysis. Int J Urol. 28:3262021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chiu PK, Ng CF, Semjonow A, Zhu Y,
Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese
A, et al: A multicentre evaluation of the role of the prostate
health index (PHI) in regions with differing prevalence of prostate
cancer: Adjustment of PHI reference ranges is needed for European
and Asian settings. Eur Urol. 75:558–561. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cheng YT, Huang CY, Chen CH, Chiu ST, Hong
JH, Pu YS, Liu SP, Lu YC, Chang YK, Chang HC, et al: Preoperative
%p2PSA and prostate health index predict pathological outcomes in
patients with prostate cancer undergoing radical prostatectomy. Sci
Rep. 10:7762020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Novak V, Vesely S, Luksanová H, Prusa R,
Capoun O, Fiala V, Dolejsová O, Sedlacková H, Kucera R, Stejskal J,
et al: Preoperative prostate health index predicts adverse
pathology and Gleason score upgrading after radical prostatectomy
for prostate cancer. BMC Urol. 20:1442020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Filson CP, Zhu K, Huang Y, Zheng Y,
Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, et
al: Impact of prostate health index results for prediction of
biopsy grade reclassification during active surveillance. J Urol.
208:1037–1045. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
de la Calle CM, Jing Y, Mamawala MM,
Landis P, Macura KJ, Trock BJ, Epstein JI, Sokoll LJ and Pavlovich
CP: Baseline prostate health index risk category and risk category
changes during active surveillance predict grade reclassification.
Urol Oncol. 41:455.e1–455.e6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mathieu R, Castelli C, Fardoun T,
Peyronnet B, Shariat SF, Bensalah K and Vincendeau S: Cost analysis
of prostate cancer detection including the prostate health index
(phi). World J Urol. 37:481–487. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen E, Cario CL, Leong L, Lopez K,
Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, et al:
Cell-free DNA concentration and fragment size as a biomarker for
prostate cancer. Sci Rep. 11:50402021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Falagario UG, Martini A, Wajswol E, Treacy
PJ, Ratnani P, Jambor I, Anastos H, Lewis S, Haines K, Cormio L, et
al: Avoiding unnecessary magnetic resonance imaging (MRI) and
biopsies: Negative and positive predictive value of MRI according
to Prostate-specific antigen density, 4Kscore and risk calculators.
Eur Urol Oncol. 3:700–704. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stejskal J, Adamcová V, Záleský M, Novák
V, Čapoun O, Fiala V, Dolejšová O, Sedláčková H, Veselý Š and
Zachoval R: The predictive value of the prostate health index vs.
multiparametric magnetic resonance imaging for prostate cancer
diagnosis in prostate biopsy. World J Urol. 39:1889–1895. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chiu PK, Lam TY, Ng CF, Teoh JY, Cho CC,
Hung HY, Hong C, Roobol MJ, Chu WC, Wong SY and Sung JJ: The
combined role of MRI prostate and prostate health index in
improving detection of significant prostate cancer in a screening
population of Chinese men. Asian J Androl. 25:674–679. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Assel M, Sjöblom L, Murtola TJ, Talala K,
Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T,
et al: A Four-kallikrein panel and β-Microseminoprotein in
predicting High-grade prostate cancer on biopsy: An independent
replication from the Finnish section of the European randomized
study of screening for prostate cancer. Eur Urol Focus. 5:561–567.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nordström T, Jäderling F, Carlsson S, Aly
M, Grönberg H and Eklund M: Does a novel diagnostic pathway
including blood-based risk prediction and MRI-targeted biopsies
outperform prostate cancer screening using prostate-specific
antigen and systematic prostate biopsies?-protocol of the
randomised study STHLM3MRI. BMJ Open. 9:e0278162019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bhattu AS, Zappala SM, Parekh DJ and
Punnen S: A 4Kscore Cut-off of 7.5% for prostate biopsy decisions
provides high sensitivity and negative predictive value for
significant prostate cancer. Urology. 148:53–58. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rasmussen M, Fredsøe J, Tin AL, Vickers
AJ, Ulhøi B, Borre M, Eastham J, Ehdaie B, Guillonneau B, Laudone
V, et al: Independent validation of a pre-specified four-Kallikrein
marker model for prediction of adverse pathology and biochemical
recurrence. Br J Cancer. 126:1004–1009. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vertosick EA, Zappala S, Punnen S,
Hugosson J, Boorjian SA, Haese A, Carroll P, Cooperberg M, Bjartell
A, Lilja H and Vickers AJ: Individual patient data Meta-analysis of
discrimination of the four Kallikrein panel associated with the
inclusion of prostate volume. Urology. 157:102–106. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guerard T, Porto JG, Fekete T, Nativ O,
Reid G, Williams A, Ryan J, Zhou K, Cortizas E, Freitas P, et al:
4K density: Adjusting the 4Kscore for prostate volume to improve
risk stratification of clinically significant prostate cancer in
men undergoing prostate biopsy. Prostate Cancer Prostatic Dis.
29:411–417. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen WS, Aggarwal R, Zhang L, Zhao SG,
Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, et al:
Genomic drivers of poor prognosis and enzalutamide resistance in
metastatic Castration-resistant prostate cancer. Eur Urol.
76:562–571. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Beltran H, Romanel A, Conteduca V,
Casiraghi N, Sigouros M, Franceschini GM, Orlando F, Fedrizzi T, Ku
SY, Dann E, et al: Circulating tumor DNA profile recognizes
transformation to castration-resistant neuroendocrine prostate
cancer. J Clin Invest. 130:1653–1668. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tukachinsky H, Madison RW, Chung JH,
Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L,
Graf RP, et al: Genomic analysis of circulating tumor DNA in 3,334
patients with advanced prostate cancer identifies targetable BRCA
alterations and AR resistance mechanisms. Clin Cancer Res.
27:3094–3105. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chi KN, Barnicle A, Sibilla C, Lai Z,
Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, et
al: Detection of BRCA1, BRCA2, and ATM alterations in matched tumor
tissue and circulating tumor DNA in patients with prostate cancer
screened in PROfound. Clin Cancer Res. 29:81–91. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mizuno K, Sumiyoshi T, Okegawa T, Terada
N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N,
Hatakeyama S, et al: Clinical impact of detecting Low-frequency
variants in cell-free DNA on treatment of castration-resistant
prostate cancer. Clin Cancer Res. 27:6164–6173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sumanasuriya S, Seed G, Parr H, Christova
R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall
J, et al: Elucidating prostate cancer behaviour during treatment
via Low-pass Whole-genome sequencing of circulating tumour DNA. Eur
Urol. 80:243–253. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hennigan ST, Trostel SY, Terrigino NT,
Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV,
Atway R, Shema S, et al: Low abundance of circulating tumor DNA in
localized prostate cancer. JCO Precis Oncol. 32019.doi:
10.1200/PO.19.00176. PubMed/NCBI
|
|
63
|
Lau E, McCoy P, Reeves F, Chow K, Clarkson
M, Kwan EM, Packwood K, Northen H, He M, Kingsbury Z, et al:
Detection of ctDNA in plasma of patients with clinically localised
prostate cancer is associated with rapid disease progression.
Genome Med. 12:722020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Renaud G, Nørgaard M, Lindberg J, Grönberg
H, De Laere B, Jensen JB, Borre M, Andersen CL, Sørensen KD,
Maretty L and Besenbacher S: Unsupervised detection of fragment
length signatures of circulating tumor DNA using non-negative
matrix factorization. Elife. 11:e715692022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pope B, Park G, Lau E, Belic J, Lach R,
George A, McCoy P, Nguyen A, Grima C, Campbell B, et al:
Ultrasensitive detection of circulating tumour DNA enriches for
patients with a greater risk of recurrence of clinically localised
prostate cancer. Eur Urol. 85:407–410. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang S, Zhu G, Xu L, Zhang Q, Qiu X, Bao
H, Wu M, Zhao X, Ding T, Wang F, et al: DECIPHER-PRAD: An advanced
fragmentomics-based cell-free DNA assay for prostate cancer early
detection. Cell Commun Signal. 24:22025. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Friedemann M, Horn F, Gutewort K, Tautz L,
Jandeck C, Bechmann N, Sukocheva O, Wirth MP, Fuessel S,
Menschikowski M, et al: Increased sensitivity of detection of
RASSF1A and GSTP1 DNA fragments in serum of prostate cancer
patients: Optimisation of diagnostics using OBBPA-ddPCR. Cancers
(Basel). 13:44592021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Londra D, Mastoraki S, Bournakis E,
Zavridou M, Thanos A, Rampias T and Lianidou ES: USP44 promoter
methylation in plasma cell-free DNA in prostate cancer. Cancers
(Basel). 13:46072021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Aykanli E, Yavuzsan AH, Buyuktepe O,
Altunok V, Balikci A, Kocoglu F, Koncuk MS, Atalay N and Turkmen N:
Diagnostic value of GSTP1, RASSF1, AND RASSF2 methylation in serum
of prostate cancer patients. Urol J. 21:182–188. 2024.PubMed/NCBI
|
|
70
|
Carson JJK, Di Lena MA, Berman DM, Siemens
DR and Mueller CR: Development and initial clinical correlation of
a DNA methylation-based blood test for prostate cancer. Prostate.
80:1038–1042. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Winter JM, Sheehan-Hennessy L, Yao B,
Pedersen SK, Wassie MM, Eaton M, Chong M, Young GP and Symonds EL:
Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and
tissues of colorectal, breast and prostate cancer patients. Cancer
Biomark. 34:493–503. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Berchuck JE, Baca SC, McClure HM,
Korthauer K, Tsai HK, Nuzzo PV, Kelleher KM, He M, Steinharter JA,
Zacharia S, et al: Detecting neuroendocrine prostate cancer through
Tissue-informed cell-free DNA methylation analysis. Clin Cancer
Res. 28:928–938. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Franceschini GM, Quaini O, Mizuno K,
Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A,
Benelli M, et al: Noninvasive detection of neuroendocrine prostate
cancer through targeted Cell-free DNA methylation. Cancer Discov.
14:424–445. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Gil-Sousa D, Oliveira-Reis D, Tavares C,
Teves F, Osório L, Gomes M, Soares J and Fraga A: Prostate biopsy
evolution and the need for repeat biopsy-The role of image and new
prostate cancer biomarkers. Arch Esp Urol. 72:677–689.
2019.PubMed/NCBI
|
|
75
|
Brönimann S, Pradere B, Karakiewicz P,
Huebner NA, Briganti A and Shariat SF: An up-to-date catalogue of
urinary markers for the management of prostate cancer. Curr Opin
Urol. 30:684–688. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Rodríguez SVM and García-Perdomo HA:
Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to
first prostate biopsy: A systematic review and meta-analysis. Can
Urol Assoc J. 14:E214–E219. 2020.PubMed/NCBI
|
|
77
|
Wendrich K and Krabbenborg L: The use of
molecular biomarker tests: An interview study with healthcare
providers about a molecular biomarker test for prostate cancer. Per
Med. 18:471–482. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lemos AEG, Matos ADR, Ferreira LB and
Gimba ERP: The long non-coding RNA PCA3: An update of its functions
and clinical applications as a biomarker in prostate cancer.
Oncotarget. 10:6589–6603. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Newcomb LF, Zheng Y, Faino AV,
Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A,
Fabrizio MD, Gleave ME, et al: Performance of PCA3 and TMPRSS2: ERG
urinary biomarkers in prediction of biopsy outcome in the Canary
Prostate Active Surveillance Study (PASS). Prostate Cancer
Prostatic Dis. 22:438–445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Trifunovski A, Dimovski A, Dohcev S,
Stavridis S, Stankov O, Saidi S, Gjorgjievska M and Popov Z:
Detection of TMPRSS2-ERG fusion transcript in biopsy specimen of
prostate cancer patients: A single Centre experience. Pril (Makedon
Akad Nauk Umet Odd Med Nauki). 41:5–14. 2020.PubMed/NCBI
|
|
81
|
Warli SM, Warli MH and Prapiska FF: PCA3
and TMPRSS2: ERG urine level as diagnostic biomarker of prostate
cancer. Res Rep Urol. 15:149–155. 2023.PubMed/NCBI
|
|
82
|
Tosoian JJ, Trock BJ, Morgan TM, Salami
SS, Tomlins SA, Spratt DE, Siddiqui J, Kunju LP, Botbyl R, Chopra
Z, et al: Use of the MyProstateScore test to rule out clinically
significant cancer: Validation of a straightforward clinical
testing approach. J Urol. 205:732–739. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lebastchi AH, Russell CM, Niknafs YS,
Eyrich NW, Chopra Z, Botbyl R, Kabeer R, Osawa T, Siddiqui J,
Siddiqui R, et al: Impact of the MyProstateScore (MPS) test on the
clinical decision to undergo prostate biopsy: Results from a
contemporary academic practice. Urology. 145:204–210. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Rubio-Briones J, Borque-Fernando A,
Esteban LM, Mascarós JM, Ramírez-Backhaus M, Casanova J, Collado A,
Mir C, Gómez-Ferrer A, Wong A, et al: Validation of a 2-gene mRNA
urine test for the detection of ≥GG2 prostate cancer in an
opportunistic screening population. Prostate. 80:500–507. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hendriks RJ, van der Leest MMG, Israël B,
Hannink G, YantiSetiasti A, Cornel EB, Hulsbergen-van de Kaa CA,
Klaver OS, Sedelaar JPM, Van Criekinge W, et al: Clinical use of
the SelectMDx urinary-biomarker test with or without mpMRI in
prostate cancer diagnosis: A prospective, multicenter study in
biopsy-naïve men. Prostate Cancer Prostatic Dis. 24:1110–1119.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tutrone R, Donovan MJ, Torkler P,
Tadigotla V, McLain T, Noerholm M, Skog J and McKiernan J: Clinical
utility of the exosome based ExoDx Prostate(IntelliScore) EPI test
in men presenting for initial Biopsy with a PSA 2–10 ng/mL.
Prostate Cancer Prostatic Dis. 23:607–614. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora
NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, et al:
Development and validation of an 18-Gene urine test for High-Grade
prostate cancer. JAMA Oncol. 10:726–736. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li Y, Ji J, Lyu J, Jin X, He X, Mo S, Xu
H, He J, Cao Z, Chen X, et al: A novel urine exosomal lncRNA assay
to improve the detection of prostate cancer at initial biopsy: A
retrospective multicenter diagnostic feasibility study. Cancers
(Basel). 13:40752021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tao W, Wang BY, Luo L, Li Q, Meng ZA, Xia
TL, Deng WM, Yang M, Zhou J, Zhang X, et al: A urine extracellular
vesicle lncRNA classifier for high-grade prostate cancer and
increased risk of progression: A multi-center study. Cell Rep Med.
4:1012402023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Davey M, Benzina S, Savoie M, Breault G,
Ghosh A and Ouellette RJ: Affinity captured urinary extracellular
vesicles provide mRNA and miRNA biomarkers for improved accuracy of
prostate cancer detection: A pilot study. Int J Mol Sci.
21:83302020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang N, Wang J, Zhang S, Wu H, Li Z and
Hu M: Development and validation of a urinary microRNA biomarker
panel as a tool for early detection of prostate cancer in a Chinese
population. Biomarkers. 28:372–378. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Ding T, Diao Y, Fu R, Gong C, He Q, He W,
Zhang L, Yang X, Zeng X, Yu L, et al: The significance of urine
extracellular vesicle DNA methylation detection in the diagnosis
and classification of prostate cancer. J Adv Res. 84:975–989. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Nyberg T, Tischkowitz M and Antoniou AC:
BRCA1 and BRCA2 pathogenic variants and prostate cancer risk:
Systematic review and meta-analysis. Br J Cancer. 126:1067–1081.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Stastna B, Dolezalova T, Matejkova K,
Nemcova B, Zemankova P, Janatova M, Kleiblova P, Soukupova J and
Kleibl Z: Germline pathogenic variants in the MRE11, RAD50, and NBN
(MRN) genes in cancer predisposition: A systematic review and
meta-analysis. Int J Cancer. 155:1604–1615. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Aoki M, Matsui H, Kurihara S, Ohtake N,
Nakazawa S, Tsuji Y, Fujizuka Y and Arai S: Comparison of BRCA2
single nucleotide variants between Japanese patients with familial
prostate cancer, sporadic prostate cancer, and benign prostatic
hyperplasia. Anticancer Res. 45:2195–2204. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Bancroft EK, Page EC, Brook MN, Thomas S,
Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, et al:
A prospective prostate cancer screening programme for men with
pathogenic variants in mismatch repair genes (IMPACT): Initial
results from an international prospective study. Lancet Oncol.
22:1618–1631. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wokołorczyk D, Kluźniak W, Stempa K, Rusak
B, Huzarski T, Gronwald J, Gliniewicz K, Kashyap A, Morawska S,
Dębniak T, et al: PALB2 mutations and prostate cancer risk and
survival. Br J Cancer. 125:569–575. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Berchuck JE, Boiarsky D, Silver R, Sunkara
R, McClure HM, Tsai HK, Siegmund S, Tewari AK, Nowak JA, Lindeman
NI, et al: Addition of germline testing to Tumor-Only sequencing
improves detection of pathogenic germline variants in men with
advanced prostate cancer. JCO Precis Oncol. 6:e22003292022.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Shi Z, Lu L, Resurreccion WK, Yang W, Wei
J, Wang Q, Engelmann V, Zheng SL, Cooney KA, Isaacs WB, et al:
Association of germline rare pathogenic mutations in
guideline-recommended genes with prostate cancer progression: A
meta-analysis. Prostate. 82:107–119. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Shore N, Gazi M, Pieczonka C, Heron S,
Modh R, Cahn D, Belkoff LH, Berger A, Mazzarella B, Veys J, et al:
Efficacy of national comprehensive cancer network guidelines in
identifying pathogenic germline variants among unselected patients
with prostate cancer: The PROCLAIM trial. Eur Urol Oncol.
6:477–483. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Mateo J, Seed G, Bertan C, Rescigno P,
Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B,
Clarke M, et al: Genomics of lethal prostate cancer at diagnosis
and castration resistance. J Clin Invest. 130:1743–1751. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
de Bono JS, Mehra N, Scagliotti GV, Castro
E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, et
al: Talazoparib monotherapy in metastatic castration-resistant
prostate cancer with DNA repair alterations (TALAPRO-1): An
open-label, phase 2 trial. Lancet Oncol. 22:1250–1264. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Mateo J, de Bono JS, Fizazi K, Saad F,
Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A,
et al: Olaparib for the treatment of patients with metastatic
Castration-resistant prostate cancer and alterations in BRCA1
and/or BRCA2 in the PROfound trial. J Clin Oncol. 42:571–583. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Akamatsu S, Terada N, Takata R, Kinoshita
H, Shimatani K, Momozawa Y, Yamamoto M, Tada H, Kawamorita N,
Narita S, et al: Clinical utility of germline genetic testing in
japanese men undergoing prostate biopsy. JNCI Cancer Spectr.
6:pkac0012022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Conti DV, Darst BF, Moss LC, Saunders EJ,
Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, et
al: Trans-ancestry genome-wide association meta-analysis of
prostate cancer identifies new susceptibility loci and informs
genetic risk prediction. Nat Genet. 53:65–75. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chen F, Madduri RK, Rodriguez AA, Darst
BF, Chou A, Sheng X, Wang A, Shen J, Saunders EJ, Rhie SK, et al:
Evidence of novel susceptibility variants for prostate cancer and a
multiancestry polygenic risk score associated with aggressive
disease in men of African ancestry. Eur Urol. 84:13–21. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Nordström T, Discacciati A, Bergman M,
Clements M, Aly M, Annerstedt M, Glaessgen A, Carlsson S, Jäderling
F, Eklund M, et al: Prostate cancer screening using a combination
of risk-prediction, MRI, and targeted prostate biopsies
(STHLM3-MRI): A prospective, population-based, randomised,
open-label, non-inferiority trial. Lancet Oncol. 22:1240–1249.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chen F, Darst BF, Madduri RK, Rodriguez
AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, et
al: Validation of a multi-ancestry polygenic risk score and
age-specific risks of prostate cancer: A meta-analysis within
diverse populations. Elife. 11:e783042022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Goss LB, Liu M, Zheng Y, Guo B, Conti DV,
Haiman CA, Kachuri L, Catalona WJ, Witte JS, Lin DW, et al:
Polygenic risk score and upgrading in patients with prostate cancer
receiving active surveillance. JAMA Oncol. 11:168–171. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Korn SM, Qian Z, Zurl H, Piccolini A, Pohl
KK, Lipsitz S, Zhang J, Kibel AS, Moore CM, Rana HQ, et al:
Disparities in tissue-based biomarker testing among US Medicare
beneficiaries with prostate cancer. JNCI Cancer Spectr.
9:pkaf0512025. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Luo Y, Hong CQ, Huang BL, Ding TY, Chu LY,
Zhang B, Qu QQ, Li XH, Liu CT, Peng YH, et al: Serum insulin-like
growth factor binding protein-3 as a potential biomarker for
diagnosis and prognosis of oesophageal squamous cell carcinoma. Ann
Med. 54:2153–2166. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Lyu Y, Guo C and Zhang H: Fatty acid
metabolism-related genes in bronchoalveolar lavage fluid unveil
prognostic and immune infiltration in idiopathic pulmonary
fibrosis. Front Endocrinol (Lausanne). 13:10015632022. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Miao Y, Su B, Tang X, Wang J, Quan W, Chen
Y and Mi D: Construction and validation of m6 A RNA methylation
regulators associated prognostic model for gastrointestinal cancer.
IET Syst Biol. 16:59–71. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Miller HA, van Berkel VH and Frieboes HB:
Lung cancer survival prediction and biomarker identification with
an ensemble machine learning analysis of tumor core biopsy
metabolomic data. Metabolomics. 18:572022. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Hao S, Discacciati A, Eklund M, Heintz E,
Östensson E, Elfström KM, Clements MS and Nordström T:
Cost-effectiveness of prostate cancer screening using magnetic
resonance imaging or standard biopsy based on the STHLM3-MRI study.
JAMA Oncol. 9:88–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Israël B, Hannink G, Barentsz JO and van
der Leest MMG: Implications of the european association of urology
recommended risk assessment algorithm for early prostate cancer
detection. Eur Urol Open Sci. 43:1–4. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hu P, Lei L, Wang Y, Tian X, Wei X, Jiang
N and Liu L: CLDN4 as a novel diagnostic and prognostic biomarker
and its association with immune infiltrates in ovarian cancer.
Mediators Inflamm. 2023:10752652023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chen X, Liu G and Wu B: Analysis and
experimental validation of the innate immune gene PSMD1 in liver
hepatocellular carcinoma and pan-cancer. Heliyon. 9:e211642023.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Cong R, Li M, Xu W, Ma X and Wang S:
Development and validation of a prognostic nomogram model
incorporating routine laboratory biomarkers for preoperative
patients with endometrial cancer. BMC Cancer. 23:11672023.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
de Jong JJ, Pijpers OM, van Kessel KEM,
Boormans JL, Van Criekinge W, Zwarthoff EC and Lotan Y: A
Urine-based genomic assay improves risk stratification for patients
with High-risk hematuria stratified according to the American
urological association guidelines. Eur Urol Oncol. 6:183–189. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lin J, Meng Y, Song MF and Gu W:
Network-Based analysis reveals novel biomarkers in peripheral blood
of patients with preeclampsia. Front Mol Biosci. 9:7572032022.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Marsden T, McCartan N, Brown L,
Rodriguez-Justo M, Syer T, Brembilla G, Van Hemelrijck M, Coolen T,
Attard G, Punwani S, et al: The ReIMAGINE prostate cancer risk
study protocol: A prospective cohort study in men with a suspicion
of prostate cancer who are referred onto an MRI-based diagnostic
pathway with donation of tissue, blood and urine for biomarker
analyses. PLoS One. 17:e02596722022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Meng C, Wang F, Chen M, Shi H, Zhao L and
Wang P: Construction and verification of nomogram model for lung
adenocarcinoma with ≤5 bone-only metastases basing on hematology
markers. Front Oncol. 12:8586342022. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Hua X, Duan F, Zhai W, Song C, Jiang C,
Wang L, Huang J, Lin H and Yuan Z: A Novel Inflammatory-Nutritional
prognostic scoring system for patients with Early-stage breast
cancer. J Inflamm Res. 15:381–394. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chen L, Hua J and He X: Identification of
cuproptosis-related molecular subtypes as a biomarker for
differentiating active from latent tuberculosis in children. BMC
Genomics. 24:3682023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Mo LC, Zhang XJ, Zheng HH, Huang XP, Zheng
L, Zhou ZR and Wang JJ: Development of a novel nomogram for
predicting clinically significant prostate cancer with the prostate
health index and multiparametric MRI. Front Oncol. 12:10688932022.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ku AT, Shankavaram U, Trostel SY, Zhang H,
Kartal S, Sater HA, Harmon SA, Carrabba NV, Liu Y, Ryu H, et al:
Radiogenomic profiling of prostate tumors prior to external beam
radiotherapy converges on a transcriptomic signature of TGF-β
activity driving tumor recurrence. Clin Cancer Res. 31:5211–5224.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Abbadi A, Eklund M, Lantz A, Discacciati
A, Björnebo L, Palsdottir T, Chandra Engel J, Jäderling F,
Falagario U, Grönberg H and Nordström T: Evaluating the performance
of existing tools to predict clinically significant prostate cancer
in men with indeterminate lesions on biparametric MRI and
development of a novel multiplex model: A prospective cohort study.
EClinicalMedicine. 82:1031912025. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Luo C, He S, Zhang H, He S, Qi H and Wei
A: Clinical and biological significance of DNA Methylation-driven
differentially expressed genes in biochemical recurrence after
radical prostatectomy. Front Genet. 13:7273072022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Govers TM, Resnick MJ, Rastinehad AR, Caba
L, Groskopf J and van Criekinge W: Cost-effectiveness of an urinary
biomarker panel in combination with MRI for prostate cancer
diagnosis. World J Urol. 41:1527–1532. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
He L, Wang X, Jin Y, Xu W, Lyu J, Guan Y,
Wu J, Han S and Liu G: A prognostic nomogram for predicting overall
survival in pediatric Wilms tumor based on an Autophagy-related
gene signature. Comb Chem High Throughput Screen. 25:1385–1397.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Huang G, Jin Q, Li M, Tian X, Mao Y and Li
Y: The potential value of low-level serum interleukin-38 for the
clinical diagnosis and risk prediction of hyperuricemia. Int
Immunopharmacol. 110:1090692022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Hou F, Zhang Q, Zhang W, Xiang C, Zhang G,
Wang L, Zheng Z, Guo Y, Chen Z, Hernesniemi J, et al: A correlation
and prediction study of the poor prognosis of high-grade aneurysmal
subarachnoid hemorrhage from the neutrophil percentage to albumin
ratio. Clin Neurol Neurosurg. 230:1077882023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Rojo Domingo M, Do DD, Conlin CC, Bagrodia
A, Barrett T, Baxter MT, Cooperberg M, Feng F, Hahn ME,
Harisinghani M, et al: Restriction spectrum imaging as a
quantitative biomarker for prostate cancer with reliable positive
predictive value. J Urol. 214:259–271. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Kan Y, Lu X, Feng L, Yang X, Ma H, Gong J
and Yang J: RPP30 is a novel diagnostic and prognostic biomarker
for gastric cancer. Front Genet. 13:8880512022. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Cauz-Valero T, Herrera-López EE, Scavuzzo
A, Calvo-Vázquez I, Ramírez-González A, Hurtado-Vázquez A,
Reynoso-Noverón N, Pérez-Camargo DA and Jímenez-Ríos MÁ: Phase
angle as a prognostic factor of survival in patients with
metastatic prostate cancer. Clin Nutr ESPEN. 70:413–419. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chang Z, Duan Z, Li J and Meng X: An
ultrasensitive sandwich-type electrochemical immunosensor for PSA
detection: Employing layer-by-layer self-assembly with
poly(thionine)/carbon nanotube multilayers as electron mediators
and Hemin-functionalized PEI/SiO2 nanoparticles as
signal amplifiers. Anal Methods. 17:8671–8683. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Alshaker H, Mills R, Hunter E, Salter M,
Ramadass A, Skinner BM, Westra W, Green J, Akoulitchev A, Winkler M
and Pchejetski D: Chromatin conformation changes in peripheral
blood can detect prostate cancer and stratify disease risk groups.
J Transl Med. 19:462021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Bernardino RMM, Leão R, Henrique R,
Pinheiro LC, Kumar P, Suravajhala P, Beck HC, Carvalho AS and
Matthiesen R: Extracellular vesicle proteome in prostate cancer: A
comparative analysis of mass spectrometry studies. Int J Mol Sci.
22:136052021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Pang B, Wang Q, Chen H, Liu Z, Han M, Gong
J, Yue L, Ding X, Wang S, Yan Z, et al: Proteomic identification of
small extracellular vesicle proteins LAMB1 and histone H4 for
prostate cancer diagnosis and risk stratification. Adv Sci (Weinh).
11:e24025092024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Modlin IM, Kidd M, Drozdov IA, Boegemann
M, Bodei L, Kunikowska J, Malczewska A, Bernemann C, Koduru SV and
Rahbar K: Development of a multigenomic liquid biopsy (PROSTest)
for prostate cancer in whole blood. Prostate. 84:850–865. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Rahbar K, Kidd M, Prasad V, David Rosin R,
Drozdov I and Halim A: Clinical sensitivity and specificity of the
PROSTest in an American cohort. Prostate. 85:558–566. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Fitzgerald J, Higgins D, Mazo Vargas C,
Watson W, Mooney C, Rahman A, Aspell N, Connolly A, Aura Gonzalez C
and Gallagher W: Future of biomarker evaluation in the realm of
artificial intelligence algorithms: Application in improved
therapeutic stratification of patients with breast and prostate
cancer. J Clin Pathol. 74:429–434. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Azadi Moghadam P, Bashashati A and
Goldenberg SL: Artificial intelligence and pathomics: Prostate
cancer. Urol Clin North Am. 51:15–26. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Cuocolo R, Comelli A, Stefano A, Benfante
V, Dahiya N, Stanzione A, Castaldo A, De Lucia DR, Yezzi A and
Imbriaco M: Deep learning Whole-gland and zonal prostate
segmentation on a public MRI dataset. J Magn Reson Imaging.
54:452–459. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Thimansson E, Bengtsson J, Baubeta E,
Engman J, Flondell-Sité D, Bjartell A and Zackrisson S: Deep
learning algorithm performs similarly to radiologists in the
assessment of prostate volume on MRI. Eur Radiol. 33:2519–2528.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Qiao P, Zhang D, Zeng S, Wang Y, Wang B
and Hu X: Using machine learning method to identify MYLK as a novel
marker to predict biochemical recurrence in prostate cancer.
Biomark Med. 15:29–41. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Tong Y, Tan Z, Wang P and Gao X: A machine
learning method for predicting biomarkers associated with prostate
cancer. Front Biosci (Landmark Ed). 28:3332023. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Choi JY, Park S, Shim JS, Park HJ, Kuh SU,
Jeong Y, Park MG, Noh TI, Yoon SG, Park YM, et al: Explainable
artificial intelligence-driven prostate cancer screening using
exosomal multi-marker based dual-gate FET biosensor. Biosens
Bioelectron. 267:1167732025. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Jain S, Malhotra KPK, Patiyal S and
Raghava GPS: A highly accurate model for screening prostate cancer
using propensity index panel of ten genes. J Comput Biol.
30:1305–1314. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Lima T, Rodrigues JE, Manadas B, Henrique
R, Fardilha M and Vitorino R: A peptide-centric approach to analyse
quantitative proteomics data-an application to prostate cancer
biomarker discovery. J Proteomics. 272:1047742023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Liu W, Yu M, Cheng S, Zhou X, Li J, Lu Y,
Liu P and Ding S: tRNA-Derived RNA fragments are novel biomarkers
for diagnosis, prognosis, and tumor subtypes in prostate cancer.
Curr Oncol. 30:981–999. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Li Q, Tang L, Zhao Y, Li Z, Ma W and Ma L:
Liquid biopsy in prostate cancer: A novel dual biomarker analysis
approach integrating circulating tumor cells and circulating tumor
DNA data. Cell Mol Biol (Noisy-le-grand). 70:158–163. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Carvalho M, Gomes RM, Moreira Rocha S,
Barroca-Ferreira J, Maia CJ, Guillade L, Correa-Duarte MA,
Passarinha LA and Moreira FTC: Development of a novel
electrochemical biosensor based on plastic antibodies for detection
of STEAP1 biomarker in cancer. Bioelectrochemistry. 152:1084612023.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Felici E, Regiart MD, Pereira SV, Ortega
FG, Angnes L, Messina GA and Fernández-Baldo MA: Microfluidic
platform integrated with carbon Nanofibers-Decorated gold
nanoporous sensing device for serum PSA quantification. Biosensors
(Basel). 13:3902023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Li Y, Liu ML, Yang WJ, Zhou XM, Zhuo Y and
He XJ: Programmable spherical nucleic acids integrated with
MOF-confined copper nanoclusters facilitate
electrochemiluminescence detection of prostate-specific biomarkers.
J Mater Chem B. 13:6342–6350. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zheng H, Zhang H, Wu J, Jiao Z and Chen Y:
Self-reporting plasmonic nanoflowers enable magnetically enriched
SERS immunoassay for ultrasensitive prostate cancer biomarker
detection. Biosens Bioelectron. 288:1178492025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Gupta VK, Cortese BD and Talwar R:
Cost-effectiveness of serum, urine, and tissue-based prostate
cancer biomarkers. Curr Opin Urol. 35:412–417. 2025. View Article : Google Scholar : PubMed/NCBI
|
